Skip to content
Alligator Bioscience

Alligator Bioscience

  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • ADC-1013
      • ATOR-1015
      • ATOR-1017
      • ALG.APV-527
      • ATOR-1144
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors and collaborators
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Frontier – A magazine about Alligator
    • Subscribe
  • Contact
  • SV
Start > News > Frontier – A magazine about Alligator
  • Frontier – A magazine about Alligator
  • Frontier #1 2019
  • Frontier #2 2018
  • Frontier #1 2018

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB

We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.I agreeI do not agree
Återkalla cookies